Recombinant Human 5-hydroxytryptamine receptor 2A (HTR2A), Truncated

Uniprot Id

P28223

Target Species

Human

Target Name

HTR2A

Target Full Name

5-hydroxytryptamine receptor 2A

Target Function

G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.; (Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.

Target Subcellular Location

Cell membrane; Multi-pass membrane protein. Cell projection, dendrite. Cell projection, axon. Cytoplasmic vesicle. Membrane, caveola. Cell junction, synapse, presynapse.

Target Protein Families

G-protein coupled receptor 1 family

Target Tissue Specificity

Detected in brain cortex (at protein level). Detected in blood platelets.

Target Synonyms

HTR2A; HTR2; 5-hydroxytryptamine receptor 2A; 5-HT-2; 5-HT-2A; Serotonin receptor 2A

Target Background

This gene encodes one of the receptors for serotonin, a neurotransmitter with many roles. Mutations in this gene are associated with susceptibility to schizophrenia and obsessive-compulsive disorder, and are also associated with response to the antidepressant citalopram in patients with major depressive disorder (MDD). MDD patients who also have a mutation in intron 2 of this gene show a significantly reduced response to citalopram as this antidepressant downregulates expression of this gene. Multiple transcript variants encoding different isoforms have been found for this gene.